ImmunityBio, Inc. (IBRX) Shareholders & Insider Trades
ImmunityBio shareholders at a glance
The largest holder of ImmunityBio stock is Patrick Soon-Shiong37.07 %, with 392.9 million shares (37.07% of the company), worth about $3.12 billion as of September 25, 2026. The 10 largest holders together own 73.4%.
In Q2 2026, 443 institutional holdings reports listed 206.0 million shares worth $2.19 billion, up 15.1% in shares from Q1 2026.
Insiders reported 10 transactions in the last two years: no sales and no purchases. The newest one on file is from February 21, 2025 (Soon-Shiong Patrick, Officer, Director and Beneficial Owner).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through February 21, 2025.
ImmunityBio, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest ImmunityBio shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Patrick Soon-Shiong37.07 % | 392.9 million | 37.07% | $3.1B |
| Cambridge Equities LP | 261.7 million | 24.69% | $2.1B |
| BlackRock Advisors LLC | 30.8 million | 2.91% | $245.0M |
| State Street Corporation | 21.4 million | 2.02% | $170.0M |
| Vanguard Portfolio Management LLC | 17.9 million | 1.69% | $142.0M |
| Vanguard Capital Management LLC | 15.7 million | 1.48% | $125.0M |
| D.E. Shaw & Co., Inc. | 11.6 million | 1.09% | $92.0M |
| Two Sigma Investments LP | 11.1 million | 1.05% | $88.0M |
| Geode Capital Management LLC | 9.8 million | 0.93% | $78.0M |
| Millennium Management LLC | 5.6 million | 0.53% | $44.0M |
As of September 25, 2026.
ImmunityBio institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 443 | 206.0 million | $2.2B |
| Q1 2026 | 421 | 179.0 million | $1.4B |
| Q4 2025 | 294 | 170.0 million | $339.0M |
| Q3 2025 | 284 | 151.0 million | $371.0M |
| Q2 2025 | 262 | 126.0 million | $332.0M |
| Q1 2025 | 228 | 79.6 million | $240.0M |
| Q4 2024 | 220 | 82.7 million | $212.0M |
| Q3 2024 | 199 | 69.9 million | $260.0M |
Shares and value held by institutions that file quarterly holdings reports (options not included).
ImmunityBio insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Soon-Shiong Patrick | Feb 21, 2025 | Officer, Director and Beneficial Owner | -- | – |
| Simon Barry J. M.D. | Feb 21, 2025 | Director | -- | – |
| Adcock Richard | Feb 21, 2025 | Chief Executive Officer | -- | – |
| Sachs David C | Feb 21, 2025 | Chief Financial Officer | -- | – |
| Lauer Regan J | Feb 21, 2025 | Officer | -- | – |
| Simon Barry J. M.D. | Jan 22, 2025 | Director | Conversion of Exercise of derivative security at price 2.00 per share. | $219,864 |
| Adcock Richard | Dec 31, 2024 | Chief Executive Officer | -- | – |
| Sachs David C | Dec 31, 2024 | Chief Financial Officer | -- | – |
| Lauer Regan J | Dec 13, 2024 | Officer | -- | – |
| Soon-Shiong Patrick | Dec 10, 2024 | Officer, Director and Beneficial Owner | Conversion of Exercise of derivative security at price 1.94 - 2.28 per share. | $231.4M |
Newest 10 of 10 insider transactions in the last two years.
Questions and answers
Who owns the most ImmunityBio stock?
Patrick Soon-Shiong37.07 %, with 37.07% of the company (as of September 25, 2026). Next: Cambridge Equities LP (24.69%) and BlackRock Advisors LLC (2.91%).
How many institutions own ImmunityBio stock?
443 institutional holdings reports listed ImmunityBio shares in Q2 2026, 206.0 million shares in all worth $2.19 billion.
Are ImmunityBio insiders buying or selling the stock?
In the last two years insiders reported no sales and no purchases (10 transactions in all); the newest on file is from February 21, 2025.
